^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    7d
    CLEE011AIC01: A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=175, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=550 --> 175
    Trial completion • Enrollment change • HEOR • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib)
    8d
    Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma (clinicaltrials.gov)
    P=N/A, N=77, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    12d
    ASSET: Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, University of Kansas Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • PGR positive
    |
    Piqray (alpelisib) • Trodelvy (sacituzumab govitecan-hziy)
    12d
    Exploration of BMI and circulating metabolic factors as predictors of metformin benefit in CCTG MA.32. (PubMed, JNCI Cancer Spectr)
    BMI and blood variables did not identify subgroups with luminal or triple negative bc who benefitted from metformin nor those with HER2 positive bc who did not benefit.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CRP (C-reactive protein) • LEP (Leptin)
    |
    HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    |
    metformin
    13d
    High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    15d
    NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden)
    |
    HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    |
    MSK-IMPACT • OncoPanel™ Assay
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    15d
    Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) (clinicaltrials.gov)
    P3, N=5270, Not yet recruiting, NRG Oncology
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PGR positive
    |
    DCISionRT
    17d
    UC-BCG-2513: Skipping Hormone Therapy in Low-Risk Early Breast Cancer (2025-523683-20-00)
    P1/2, N=630, Not yet recruiting, Unicancer
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen • letrozole • anastrozole • exemestane
    22d
    FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (clinicaltrials.gov)
    P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR positive
    26d
    PIKALO-2: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (clinicaltrials.gov)
    P3, N=920, Recruiting, Eli Lilly and Company | N=274 --> 920
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation • PGR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • tersolisib (LY4064809)
    27d
    LUBRECA: Luminal Breast Cancer Cryoablation (clinicaltrials.gov)
    P=N/A, N=140, Recruiting, Lucía Graña López | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    28d
    High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer (clinicaltrials.gov)
    P2, N=36, Suspended, City of Hope Medical Center | Trial completion date: Aug 2026 --> Jan 2027 | Recruiting --> Suspended | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive